.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,429,602

« Back to Dashboard

Claims for Patent: 7,429,602

Title:Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva
Abstract:Treating allergic conjunctivitis by administered aqueous solutions containing epinastine, optionally in the form of its racemate or its enantiomers and optionally, in the form of the pharmacologically acceptable acid addition salts thereof, to the conjunctiva.
Inventor(s): Trach; Volker (Biberach, DE), Duschler; Gerold (Ehingen, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. Kg (Ingelheim, DE)
Application Number:11/863,008
Patent Claims: 1. A method for treating allergic conjunctivitis, comprising topically administering to the conjunctiva of a host in need of such treatment a solution comprising: (a) a pharmaceutically active ingredient consisting essentially of epinastine, optionally in the form of its racemate, or an enantiomer thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.005 to 0.5 mg/ml of solution; (b) water or physiologically acceptable saline; and (c) a preservative, optionally also including one or more chelating agents, viscosity agents, penetration promoters, antioxidants, substances to adjust the tonicity of the solution, or a physiologically acceptable buffer.

2. A method for inhibiting the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva of a host to reduce the occurrence of late phase allergic reactions, comprising: topically administering to the ocular conjunctiva of the host a solution comprising: (a) a pharmaceutically active ingredient consisting essentially of epinastine, optionally in the form of its racemate, an enantiomer thereof, or a pharmacologically acceptable acid addition salt thereof, in a concentration of 0.005 to 0.5 mg/ml of solution; (b) water or physiologically acceptable saline; and (c) a preservative, optionally also including one or more chelating agents, viscosity agents, penetration promoters, antioxidants, substances to adjust the tonicity of the solution or a physiologically acceptable buffer.

3. The method of claim 1, wherein the solution comprises: (a) a pharmaceutically active ingredient consisting essentially of epinastine hydrochloride, in a concentration of about 0.5 mg/ml of solution; (b) water or physiologically acceptable saline; (c) benzalkonium chloride as a preservative; and (d) a buffer to adjust the pH within the range of 6.5 to 7.2.

4. The method of claim 2, wherein the solution comprises: (a) a pharmaceutically active ingredient consisting essentially of epinastine hydrochloride, in a concentration of about 0.5 mg/ml of solution; (b) water or physiologically acceptable saline; (c) benzalkonium chloride as a preservative; and (d) a buffer to adjust the pH within the range of 6.5 to 7.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc